| Literature DB >> 33580068 |
Rebecca K McLean1, Alexandra J Spencer2, Tobias J Tuthill1, Teresa Lambe3, Simon P Graham4, Sandra Belij-Rammerstorfer2, Daniel Wright2, Marta Ulaszewska2, Jane C Edwards1, Jack W P Hayes1, Veronica Martini1, Nazia Thakur1, Carina Conceicao1, Isabelle Dietrich1, Holly Shelton1, Ryan Waters1, Anna Ludi1, Ginette Wilsden1, Clare Browning1, Dagmara Bialy1, Sushant Bhat1, Phoebe Stevenson-Leggett1, Philippa Hollinghurst1,5, Ciaran Gilbride2, David Pulido2, Katy Moffat1, Hannah Sharpe2, Elizabeth Allen2, Valerie Mioulet1, Chris Chiu1, Joseph Newman1, Amin S Asfor1, Alison Burman1, Sylvia Crossley1, Jiandong Huo6,7, Raymond J Owens6,7, Miles Carroll8, John A Hammond1, Elma Tchilian1, Dalan Bailey1, Bryan Charleston1, Sarah C Gilbert2.
Abstract
Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.Year: 2020 PMID： 33580068 DOI： 10.1038/s41541-020-00221-3
Source DB: PubMed Journal: NPJ Vaccines ISSN： 2059-0105 Impact factor: 7.344